Frailty in the elderly describes a state of reduced homeostatic reserve and diminished resistance to external and internal stressors, which is associated with adverse outcomes such as disability, falls, and death ([@B1], [@B2]). With rising life expectancy, frailty is increasingly recognized as an important health care issue; much research has focused on investigating its etiology and natural history to help identify high-risk individuals and facilitate the development of effective prevention and treatment strategies.

The pathophysiology of frailty is poorly understood, but it has been linked with disruptions within a number of body systems, including metabolic and inflammatory pathways ([@B3], [@B4]). Both aging and frailty share common features in relation to changes in body composition, muscle strength, and physical function, which are accompanied by a parallel decline in androgen levels. Therefore, dysregulation within the hypothalamic-pituitary-gonadal axis has been suggested to play a role in the development of frailty. The supporting evidence, however, is rather limited. A number of studies have investigated associations of testosterone (T) with parameters of muscle function and physical performance ([@B5], [@B6]), but relatively few, predominantly cross-sectional, studies have focused on association between androgens and frailty ([@B7], [@B8]), with conflicting results. Moreover, to date, frailty (as opposed to muscle strength and physical performance) has not been studied as a clinical outcome of interventional trials of T replacement in older men.

We used the longitudinal data from the population-based European Male Ageing Study (EMAS) to determine the associations between hypothalamic-pituitary-gonadal axis hormones and change in frailty status in middle-aged and older men.

Methods {#s9}
=======

Subjects {#s10}
--------

Subjects included were participants in the EMAS as described previously ([@B9]). Briefly, 3369 men aged 40 to 79 were recruited between 2003 and 2005 from population-based sampling frames in eight European centers: Florence (Italy), Leuven (Belgium), Lodz (Poland), Malmö (Sweden), Manchester (United Kingdom), Santiago de Compostela (Spain), Szeged (Hungary), and Tartu (Estonia). The participants completed a series of clinical assessments and provided a fasting blood sample. Ethical approval was obtained in accordance with the local requirements.

Participants were recontacted after a minimum of 4 years (median, 4.3 years). Methods of data collection at follow-up were largely identical to the baseline study. During follow-up, 193 (6%) men died and 440 (13%) were lost to follow-up.

Participants with self-reported history of testicular, adrenal, and/or pituitary disease and/or the use of medications affecting the functioning of the hypothalamic-pituitary-gonadal axis (androgens, antiandrogens, 5-*α* reductase inhibitors, gonadotropin-releasing hormone analogs, anabolic steroids, strong opioids, and oral corticosteroids) were excluded. We did this for two reasons: 1) because we were interested in the associations of physiological, rather than pathological, differences in hormone levels with changes in frailty and 2) because the diseases causing altered hormone levels could have direct effects on frailty levels and confound the relationship between hormone levels and changes in frailty.

Assessments {#s11}
-----------

All participants were asked questions concerning lifestyle, general health, and comorbidities. The interviewer-assisted questionnaire included the Medical Outcomes Study 36-Item Short Form Survey ([@B10]), the Physical Activity Scale for the Elderly ([@B11]), Beck's Depression Inventory (BDI) ([@B12]), and the International Prostate Symptoms Score ([@B13]). Physical function was assessed by Reuben's Physical Performance Test ([@B14]) and the Tinetti Balance and Postural Stability Index ([@B15]). The Rey-Osterrieth Complex Figure Test ([@B16]), the Camden Topographical Recognition Memory Test ([@B17]), and the Digit-Symbol Substitution Test ([@B18]) were used to assess the cognitive function. Anthropometric parameters measured included height, weight, waist, mid upper arm, and calf circumferences, and skinfold thicknesses.

Frailty measures {#s12}
----------------

Frailty was characterized by the two commonly used approaches: frailty index (FI) and frailty phenotype (FP).

The EMAS FI comprised 39 health deficits (symptoms, signs, and functional and cognitive impairments) that accumulate with age and are associated with adverse health outcomes. These variables were derived from Medical Outcomes Study 36-Item Short Form Survey and BDI questionnaires, physical performance and cognitive test data, and self-reported comorbidities. The EMAS FI was created using a standardized procedure ([@B19]) and was calculated as the number of deficits present divided by the maximum number of deficits possible. Binary variables (coded as 0 or 1) indicated the absence or presence of a deficit, and intermediate responses (*e.g.*, sometimes/maybe) were coded as 0.5. Continuous variables were dichotomized based on the distribution of participants' scores (cut points set at the worst performing 10th centile) (Supplemental Table 1). Individuals with \>20% of deficit variables missing were excluded (Supplemental Figs. 3 and 4).

EMAS FP was adapted from the five criteria used in the Cardiovascular Health Study ([@B2]): sarcopenia, exhaustion, slowness, weakness, and low activity. Variables used to construct EMAS FP and population-specific frailty thresholds are presented in Supplemental Table 2, alongside the original Cardiovascular Health Study criteria. Individuals with three or more criteria were classed as "frail," those with one or two as "prefrail," and those with none as "robust" (Supplemental Fig. 5). The EMAS FP has been shown to be predictive of adverse health outcomes such as falls and death ([@B20]).

Reproductive hormones and SHBG {#s13}
------------------------------

A fasting morning (before 10 [am]{.smallcaps}) venous blood sample was taken at baseline and follow-up. A validated gas (or liquid) chromatography-mass spectrometry system was used to analyze T \[intra- and interassay coefficients of variation (CVs): 2.9% and 3.4%\], estradiol (E~2~; CVs: 3.5% and 3.7%), and dihydrotestosterone (DHT; CVs: 3.1% and 4.1%).

Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex hormone--binding globulin (SHBG) were measured using the Modular E170 platform electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Intra- and interassay CVs were 1.9% and 2.7% for LH, 0.9% and 1.9% for FSH, and 1.9% and 3.2% for SHBG.

Free T (fT) levels were derived from total T, SHBG, and albumin concentrations using Vermeulen's formula ([@B21]).

Statistical analysis {#s14}
--------------------

Descriptive statistics were presented as mean ± standard deviation (SD) or n (%), and statistical significance of between-group differences was assessed using analysis of variance.

### FI models {#s15}

In view of the right skewing of the FI variable, relationships between individual endocrine predictors and FI at follow-up (outcome) were assessed using negative binomial regression modeling. The FI metric was calibrated as an additive 0- to 39-count scale, where "0" represented no deficits and "39" represented the maximum deficits. Results were presented as percentage change \[95% confidence interval (CI)\] in FI associated with a 1 SD higher baseline hormone level (negative values indicating improving frailty and positive values indicating worsening frailty during follow-up).

### FP models {#s16}

Change in frailty was defined using transitions in frailty states between baseline and follow-up. The transitions considered were worsening frailty (robust or prefrail at baseline progressing to prefrail or frail at follow-up; referent category: persistent robust or persistent prefrail) and improving frailty (prefrail or frail at baseline transitioning to robust or prefrail state at follow-up; referent category: persistent frail or prefrail).

Logistic regression models determined relationships between individual predictors (hormones at baseline) and outcome (transition in FP). Each hormone was represented by an untransformed value and standardized as a *z* score \[(raw score -- mean)/SD\]. The results were displayed as odds ratios (ORs) with 95% CIs for a 4.3-year change in frailty status associated with a 1 SD difference in baseline hormone level.

Regression models were adjusted for baseline frailty status, age, center, smoking (current or ex-/nonsmoker), and body mass index (BMI) category (BMI \< 25, 25 to 30, and ≥ 30). These covariates were chosen because they correlated with predictors and were not components of the FP or FI. Analyses in which E~2~ was a predictor were adjusted for total T level---the main precursor for E~2~ production in men.

All analyses were performed using STATA 13 SE software (StataCorp LP, College Station, TX).

Results {#s17}
=======

Population characteristics {#s18}
--------------------------

Of the 3369 men who participated in EMAS, 2278 men remained in the FI analysis and 1980 in the FP analysis after exclusion of those with pituitary, testicular, or adrenal disease or use of medication affecting hypothalamic-pituitary-gonadal axis (n = 312), missing FI (n = 204), or FP (n = 502) data and failure to attend for follow-up assessment (n = 575) (Supplemental Fig. 1).

Compared with the main analytical sample, men lost to follow-up (n = 407) were older and had higher systolic blood pressure and greater prevalence of smoking, depression, diabetes, and frailty at baseline (Supplemental Tables 3 and 4). This was also the case for the men who died (n = 168), with addition of a higher creatinine and waist-hip ratio in this group when compared with the analytical sample (Supplemental Tables 3 and 4).

Baseline characteristics {#s19}
------------------------

Baseline clinical and hormonal characteristics of the study participants are shown in [Table 1](#T1){ref-type="table"}. The men had a mean ± SD age of 58 ± 11 years and a BMI of 28 ± 4 kg/m^2^. Six percent were known to suffer from diabetes, 33% reported history of a cardiovascular disease (CVD), and 21% had history of depression.

###### 

**Baseline Characteristics of the Study Population**

  Baseline Parameter                         Mean ± SD or n (%)
  ------------------------------------------ --------------------
  N                                          2278
  Age, y                                     58 ± 11
  BMI, kg/m^2^                               28 ± 4
  Smoking, n (%)                             447 (20%)
  Frequent alcohol, n (%)                    546 (24%)
  Systolic BP, mm Hg                         145 ± 20
  Diastolic BP, mm Hg                        87 ± 12
  PASE                                       206 ± 87
  Severe depression (BDI band 4--6), n (%)   69 (4%)
  Mild depression (BDI band 2--3), n (%)     363 (17%)
  CVD, n (%)                                 741 (33%)
  Diabetes, n (%)                            132 (6%)
  Total T, nmol/L                            16.9 ± 6.0
  fT, pmol/L                                 303.3 ± 85.9
  DHT, nmol/L                                1.34 ± 0.6
  E~2~, pmol/L                               73.6 ± 24.6
  SHBG, nmol/L                               41.8 ± 19.0
  FSH, IU/L                                  8.0 ± 8.4
  LH, IU/L                                   6.0 ± 4.0

Abbreviations: BP, blood pressure; N, number; PASE, Physical Activity Scale for the Elderly.

Differences in baseline parameters between frailty transition groups are shown in [Table 2](#T2){ref-type="table"}. When compared with men who remained robust or prefrail, those whose frailty status deteriorated over follow-up (n = 426; Supplemental Fig. 2) were older and had lower baseline BMI, but higher SHBG, LH, and FSH hormones and a higher prevalence of diabetes and CVD. When compared with men who remained persistently frail or prefrail, men who experienced improvement in their frailty status (n = 196; Supplemental Fig. 2) were younger and had a lower prevalence of CVD and lower baseline E~2~, SHBG, and gonadotropin levels.

###### 

**Baseline Parameters Stratified by Frailty Transition Group, as Assessed by FP Derived From the Cardiovascular Health Study**

  Baseline Parameter                         Worsening Frailty[*^a^*](#t2n1){ref-type="table-fn"}   Persistent Robust and Persistent Prefrail   *P* Value   Improving Frailty[*^b^*](#t2n2){ref-type="table-fn"}   Persistent Frail and Persistent Prefrail   *P* Value
  ------------------------------------------ ------------------------------------------------------ ------------------------------------------- ----------- ------------------------------------------------------ ------------------------------------------ -----------
  N                                          426                                                    1352                                                    196                                                    236                                        
  Age, y                                     60 ± 11                                                57 ± 10                                     \<0.001     59 ± 10                                                64 ± 10                                    \<0.001
  BMI, kg/m^2^                               27.3 ± 3.9                                             27.7 ± 4.0                                  0.025       27.3 ± 3.7                                             27.2 ± 5.1                                 0.322
  Smoking, n (%)                             95 (22)                                                257 (19)                                    0.145       42 (22)                                                54 (23)                                    0.771
  Frequent alcohol, n (%)                    114 (27)                                               317 (24)                                    0.174       48 (25)                                                49 (21)                                    0.378
  Systolic BP, mm Hg                         145 ± 20                                               145 ± 20                                    0.910       144 ± 21                                               147 ± 22                                   0.158
  Diastolic BP, mm Hg                        87 ± 11                                                88 ± 12                                     0.297       89 ± 13                                                86 ± 12                                    0.063
  PASE                                       192 ± 80                                               217 ± 86                                    \<0.001     158 ± 93                                               145 ± 94                                   0.124
  Severe depression (BDI band 4--6), n (%)   7 (2)                                                  33 (3)                                      0.399       8 (5)                                                  18 (11)                                    0.092
  Mild depression (BDI band 2--3), n (%)     77 (19)                                                194 (15)                                    0.064       47 (25)                                                65 (30)                                    0.280
  CVD, n (%)                                 154 (36)                                               364 (29)                                    0.006       68 (35)                                                112 (48)                                   0.007
  Diabetes, n (%)                            32 (8)                                                 63 (5)                                      0.024       10 (5)                                                 22 (9)                                     0.097
  Total T, nmol/L                            17.2 ± 6.1                                             17.0 ± 6.0                                  0.363       16.4 ± 5.8                                             17.3 ± 6.5                                 0.179
  fT, pmol/L                                 300.1 ± 83.0                                           310.3 ± 86.3                                0.076       290.1 ± 79.7                                           285.2 ± 88.9                               0.454
  DHT, nmol/L                                1.37 ± 0.6                                             1.34 ± 0.6                                  0.221       1.31 ± 0.5                                             1.37 ± 0.6                                 0.669
  E~2~, pmol/L                               74.5 ± 25.8                                            73.8 ± 24.0                                 0.668       69.8 ± 21.3                                            77.5 ± 29.8                                0.010
  SHBG, mmol/L                               43.6 ± 18.7                                            40.4 ± 17.9                                 \<0.001     42.3 ± 20.0                                            47.5 ± 19.5                                0.002
  FSH, IU/L                                  8.4 ± 7.8                                              7.3 ± 6.9                                   0.003       8.0 ± 8.9                                              9.9 ± 12.1                                 0.017
  LH, IU/L                                   6.1 ± 3.6                                              5.6 ± 3.5                                   0.010       5.7 ± 3.9                                              6.9 ± 5.5                                  0.005

Data are expressed as mean ± SD for continuous variables or as number (percentage) for binary categorical variables. *P* values were calculated using baseline parameters and using analysis of variance.

Abbreviations: BP, blood pressure; N, number; PASE, Physical Activity Scale for the Elderly.

Worsening Frailty = robust or prefrail men at baseline progressing to prefrail or frail state at follow-up.

Improving Frailty = prefrail or frail men at baseline transitioning to robust or prefrail state at follow-up.

Hormonal predictors of worsening frailty {#s20}
----------------------------------------

### FI {#s21}

In models adjusted for baseline frailty, age, center, and smoking status, higher baseline levels of total T, free T (fT), and DHT were associated with a lower likelihood of worsening FI ([Table 3](#T3){ref-type="table"}). After additional adjustment for BMI, only fT remained a significant predictor of change in FI. Higher baseline levels of SHBG, FSH, and LH were associated with higher risk of worsening FI in models adjusted for baseline FI ([Table 3](#T3){ref-type="table"}), but age adjustment attenuated these relationships. Higher E~2~ levels predicted worsening FI in a model adjusted for baseline FI, age, center, and smoking; however, the statistical significance was lost after additional adjustment for BMI ([Table 3](#T3){ref-type="table"}).

###### 

**Relationship Between Baseline Level of Endocrine Predictors and a 4-Year Percentage Change in FI**

  Models and Adjustments                                                                                                                                              
  ----------------------------------------- ------ ------ -------------- --------- ------ ------------- --------- ------ ------------- --------- ------ ------------- -------
  Total T                                   2262   −3.0   −4.9, --0.4    0.020     −3.0   −4.9, --0.5   0.015     −3.0   −5.9, --1.0   0.004     −1.0   −3.0, 1.0     0.354
  fT                                        2257   −8.6   −10.5, --5.9   \<0.001   −4.9   −7.7, --3.0   \<0.001   −3.9   −6.8, --2.0   0.001     −2.8   −4.9, --0.3   0.030
  DHT                                       2255   −3.0   −4.9, --0.6    0.013     −3.9   −6.8, --2.0   \<0.001   −3.9   −6.8, --2.0   \<0.001   −2.0   −4.0, 0.4     0.105
  E~2~[*^b^*](#t3n2){ref-type="table-fn"}   2254   1.0    −1.0, 3.0      0.389     2.0    −1.0, 4.0     0.133     3.0    −1.0, 5.1     0.027     1.0    −1.0, 4.1     0.407
  SHBG                                      2268   5.1    2.0, 7.2       \<0.001   0.4    −2.0, 2.0     0.721     −1.1   −3.0, 1.3     0.368     1.0    −1.0, 3.0     0.391
  FSH                                       2267   5.1    3.0, 7.2       \<0.001   2.0    −0.3, 4.0     0.091     1.0    −1.0, 3.1     0.311     1.0    −0.9, 3.0     0.274
  LH                                        2266   4.1    2.0, 6.0       \<0.001   2.0    −0.5, 7.0     0.113     1.0    −1.0, 3.0     0.285     1.0    −0.5, 3.0     0.138

Abbreviations: BMIc, BMI categories (\<25, 25 to 30, ≥30); N, sample size.

Change (percentage change/4 years) in FI per SD increase in hormone level. Negative percentage change means that the baseline hormone level is associated with improvement of frailty status, and positive percentage change means that the hormone is associated with worsening frailty status.

Models 2 to 4 additionally adjusted for baseline total T level.

### FP {#s22}

In keeping with the FI results, higher baseline fT levels were associated with a lower likelihood of worsening FP, but this association became statistically nonsignificant after adjusting for age ([Table 4](#T4){ref-type="table"}). Also in keeping with FI data, higher baseline SHBG, LH, and FSH levels were significantly associated with worsening FP in models adjusted for baseline FP, but age adjustment, again, attenuated these relationships. Baseline levels of T and DHT were not related to worsening FP in any model.

###### 

**Multivariable-Adjusted OR (95% CI) for Worsening FP Associated With Baseline Endocrine Predictors**

  Models and Adjustments                                                                                                                                     
  ----------------------------------------- ------ ------ ------------ --------- ------ ------------ ------- ------ ------------ ------- ------ ------------ -------
  Total T                                   1766   1.04   0.93, 1.16   0.446     1.04   0.93, 1.16   0.520   1.08   0.96, 1.22   0.187   1.05   0.92, 1.18   0.474
  fT                                        1760   0.86   0.77, 0.96   0.008     0.98   0.87, 1.1    0.702   1.03   0.91, 1.16   0.681   0.99   0.88, 0.04   0.979
  DHT                                       1759   1.07   0.96, 1.19   0.213     1.03   0.92, 1.15   0.601   1.01   0.90, 1.14   0.822   0.96   0.85, 1.09   0.574
  E~2~[*^a^*](#t4n1){ref-type="table-fn"}   1759   1.04   0.94, 1.16   0.435     0.99   0.87, 1.13   0.894   1.07   0.94, 1.23   0.300   1.11   0.97, 1.28   0.136
  SHBG                                      1769   1.25   1.12, 1.39   \<0.001   1.08   0.96, 1.22   0.181   1.10   0.97, 1.24   0.144   1.06   0.94, 1.21   0.342
  FSH                                       1768   1.21   1.09, 1.34   \<0.001   1.09   0.98, 1.22   0.123   1.11   0.99, 1.24   0.085   1.10   0.98, 1.24   0.094
  LH                                        1767   1.20   1.08, 1.33   0.001     1.09   0.97, 1.22   0.132   1.08   0.96, 0.21   0.183   1.07   0.95, 1.20   0.257

Abbreviations: BMIc, BMI categories (\<25, 25 to 30, ≥30); DM, diabetes mellitus; N, sample size.

Models 2 to 4 additionally adjusted for baseline total T level.

Hormonal predictors of improving frailty {#s23}
----------------------------------------

In prefrail or frail men, higher baseline levels of E~2~ were associated with a lower likelihood of improvement in FP at follow-up in the fully adjusted model ([Table 5](#T5){ref-type="table"}). Higher levels of SHBG and LH were associated with a lower likelihood of improving FP, but these associations became statistically nonsignificant after adjusting for age. Levels of T, fT, and DHT were not related to FP improvement in any model.

###### 

**Multivariable-Adjusted OR (95% CI) for Improving FP Associated With Baseline Endocrine Predictors**

  Models and Adjustments                                                                                                                                  
  ----------------------------------------- ----- ------ ------------ ------- ------ ------------ ------- ------ ------------ ------- ------ ------------ -------
  Total T                                   427   0.88   0.73, 1.06   0.181   0.85   0.69, 1.03   0.107   0.87   0.70, 1.07   0.183   0.87   0.69, 1.09   0.215
  fT                                        427   1.09   0.90, 1.32   0.385   0.89   0.72, 1.10   0.290   0.89   0.71, 1.11   0.319   0.90   0.71, 1.13   0.349
  DHT                                       428   0.91   0.75, 1.10   0.322   0.92   0.75, 1.12   0.413   0.94   0.76, 1.16   0.589   0.96   0.77, 1.21   0.764
  E~2~[*^a^*](#t5n1){ref-type="table-fn"}   428   0.74   0.61, 0.89   0.002   0.81   0.64, 1.01   0.061   0.71   0.56, 0.91   0.008   0.68   0.52, 0.88   0.004
  SHBG                                      429   0.76   0.63, 0.92   0.006   0.88   0.72, 1.08   0.223   0.90   0.72, 1.12   0.343   0.91   0.72, 1.15   0.446
  FSH                                       429   0.88   0.76, 1.02   0.095   0.99   0.85, 1.15   0.906   1.02   0.88, 1.18   0.804   1.02   0.88, 1.19   0.791
  LH                                        428   0.80   0.67, 0.96   0.018   0.91   0.76, 1.09   0.302   0.94   0.79, 1.12   0.484   0.94   0.79, 1.12   0.492

Abbreviations: BMIc, BMI categories (\<25, 25 to 30, ≥30); DM, diabetes mellitus; N, sample size.

Models 2 to 4 additionally adjusted for baseline total T level.

Secondary analyses {#s24}
------------------

In a secondary analysis, age modified the association between gonadotropins and FI. In the fully adjusted models, higher LH and FSH levels were related to worsening FI in younger (\<60 years old) but not older men \[percentage change in FI associated with 1 SD higher hormone level: FSH, 10% (*P* = 0.002); LH, 9.6% (*P* = 0.003)\].

In FP models, further adjustment for CVD, depression (BDI score), and diabetes did not alter the relationship between hormones and FP (Supplemental Tables 6 and 7); the association between E~2~ and improvement in FP persisted \[OR, 0.68 (0.51, 0.89); *P* = 0.005\]. FI models were not adjusted for CVD or diabetes because they are components of FI.

Discussion {#s25}
==========

Main findings {#s26}
-------------

These data describe the longitudinal associations of reproductive hormone levels with changes in frailty status in middle-aged and elderly men using two different frailty models. Our main findings were (1) higher fT levels were associated with a lower risk of worsening frailty status with consistent directions of association using two different frailty constructs (FI and FP); (2) in age-adjusted FI models, higher androgen levels (fT, T, and DHT) remained significantly associated with improving frailty status, suggesting that these relationships cannot be explained by age-related differences in androgen levels; (3) we provided evidence that frailty status was less likely to improve in prefrail or frail men with higher baseline E~2~ levels; and (4) we showed that higher LH and FSH levels were associated with worsening frailty status, but that these relationships were largely explained by age-related changes in these hormones, except in younger men.

We have previously shown that nonandrogenic anabolic hormones such as IGF-1, IGFBP3, and vitamin D were independently associated with change in frailty status in middle-aged and older men ([@B22]). These two complimentary reports enhance our understanding of a relative role of the endocrine system in the development of frailty and suggest that there may be multiple underlying hormonal mechanisms involved in the pathogenesis of frailty.

Prior studies {#s27}
-------------

This is, to our knowledge, the first study to simultaneously use two common frailty measures to investigate relationships between reproductive hormones and frailty. Furthermore, whereas the majority of frailty studies have been cross-sectional and have focused on elderly men, we investigated frailty prospectively and included younger men (40 to 59 years) to seek evidence that hormonal levels might predispose to the development of onset of frailty.

Our results contrast with those of the Concord Health and Ageing in Men Project ([@B23]), where 1166 men \>70 years of age were followed for 2.1 years. The authors found no association between baseline levels of T, fT, DHT, SHBG, or gonadotropins and worsening frailty. Moreover, the authors observed that lower levels of estrone (but not E~2~) were linked to prevalent and incident frailty, but these findings were not confirmed when an alternative measure of physical frailty (Study of Osteoporotic Fractures FI) was used ([@B23]). Methodological differences (studying much older subjects, having shorter follow-up, smaller sample size, and not adjusting for baseline frailty status) may have contributed to differences compared with our study.

Cawthon *et al*. ([@B8]) reported longitudinal associations between lower baseline bioavailable T, but not T, E~2~, or SHBG, and a higher risk of frailty at 4.1 years in 1245 men aged \>65 years participating in the Osteoporotic Fractures in Men Study. Free T was not evaluated. Adjustment for a number of covariates, including age, baseline frailty, BMI, comorbidities, education, smoking status, marital status, and self-rated health, attenuated this association. This loss of statistical significance could perhaps be explained by covariates such as BMI being on the causal pathway linking hormone levels to frailty. However, in our study, fT and E~2~ remained significantly predictive of frailty changes after covariate adjustments. Therefore, overadjustment bias is unlikely to account for the discrepant results. Notwithstanding the differences between bioavailable T and fT, it is possible that sample size, the older age range (\>65 years), and the quartile modeling methodology used by Cawthon *et al*. ([@B8]) may have mitigated against finding persistently significant relationships.

By contrast, the Health in Men Study reported statistically significant associations between baseline levels of immunoassayed T and calculated fT as well as LH and frailty measured by the FRAIL scale in 1586 men aged 70 to 88 years followed for 6 years ([@B7]). Following adjustment for age, BMI, smoking, diabetes, social support, and impaired hearing and vision, only fT remained significantly correlated with follow-up frailty status. These findings are consistent with our present results. Our study adds important new data by assessing frailty through objective and validated clinical assessments (not only questionnaires) and by assessing participants using two frailty measures in a larger and younger cohort that captures earlier frailty transitions.

FI vs FP {#s28}
--------

Although we have shown significant associations between reproductive hormones and frailty, it is important to note that relationships varied between the two different constructs of frailty assessment. Covariates, mainly age and BMI, confounded and attenuated the hormone-frailty relationships, especially those between hormones and FP. The discrepancies in the statistical significance of the results could be explained by two factors. First, the results might reflect differences in the frailty definitions used in each model; whereas FP is a measure of a physical frailty, FI is more holistic and incorporates physical, psychological, and cognitive factors. Therefore, although higher androgens were related to lower risk of worsening FI, the lack of significant associations between androgens and worsening FP might indicate that these hormones are more strongly predictive of general health rather than musculoskeletal function. Alternatively, differences in statistical modeling of "change" in frailty may explain the inconsistent associations with T and gonadotropins. FI, as a continuous measure of frailty, offers a relatively greater sensitivity to detect changes in frailty status compared with the less frequent transitions between FP categories.

Potential pathophysiological mechanisms {#s29}
---------------------------------------

Decline in muscle mass and function is thought to be central to the development of frailty, and a large body of evidence strongly supports the important anabolic role of T on the skeletal muscle. T stimulates muscle fiber hypertrophy through its action on muscle protein synthesis and inhibition of degradation pathways ([@B24]); nonetheless, the associations between T and measurements of muscle strength and physical performance remain inconsistent ([@B25], [@B26]). Additionally, low T is thought to be proinflammatory, which has been liked to frailty development ([@B27]).

Although E~2~ is thought to be related to adiposity rather than muscle function in men ([@B28]), negative associations between E~2~ and muscle mass and strength have been reported ([@B29], [@B30]). E~2~ might therefore be linked to frailty through obesity or sarcopenic obesity, a feature of frailty associated with poorer outcomes. We confirmed that the effects of E~2~ on frailty were independent of T level. Because E~2~ displays proinflammatory properties *in vivo* ([@B31]), indirect effects of E~2~ on frailty via disturbance in inflammatory pathways need to be considered. Nonetheless, further adjustment for baseline levels of high-sensitivity C-reactive protein and leptin levels did not change the associations between E~2~ and improving FP \[OR, 0.7 (0.52, 0.95); *P* = 0.022\]. The potential pathophysiological mechanisms linking E~2~ and frailty remain poorly understood and require further investigation.

Strengths and limitations {#s30}
-------------------------

This study has several strengths including: (1) use of a well-defined longitudinal, community-based cohort; (2) having a large sample size with adequate power to provide conclusive results; (3) use of standardized methods in central laboratories to assess hormone levels, including mass spectrometry; (4) use of two well-validated frailty models; and (5) the inclusion of men under 65 years of age who have not been studied previously in this context.

We acknowledge some limitations: (1) The response rate for participation was 41%. Although this is comparable to other large epidemiological studies, the occurrence of frailty in the study might have been over- or underestimated through selection. (2) One hundred ninety-three men died during follow-up, and 440 men were lost to follow-up. Therefore, the true incidence of frailty has probably been underestimated. Because this would bias the results toward the null, the reported strength of our associations are likely to be conservative. (3) Our analysis is based on the results of single hormone measurements, which do not capture pulsatile hormone variation and could attenuate regression coefficients toward the null through regression dilution bias.

Conclusion {#s31}
==========

In summary, these prospective data provide important insight into the potential role of reproductive hormones in the development, progression, and recovery of frailty in aging men. The results cannot confirm a causal relationship between androgen status and progression of frailty, but the clear associations shown here make a strong case for definitive, large interventional trials of T therapy in frail men to determine whether such treatment would be beneficial. We show that raised gonadotropins in men \<60 years old might be an early marker of frailty and accelerated aging and suggest that the role of E~2~ in frailty requires further investigation.

Abbreviations: BDIBeck's Depression InventoryBMIbody mass indexCIconfidence intervalCVcoefficient of variationCVDcardiovascular diseaseDHTdihydrotestosteroneE~2~estradiolEMASEuropean Male Ageing StudyFIfrailty indexFPfrailty phenotypeFSHfollicle-stimulating hormonefTfree testosteroneLHluteinizing hormoneORodds ratioSDstandard deviationSHBGsex hormone--binding globulinTtestosterone.
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